REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting [Yahoo! Finance]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
data from the Phase II ALTITUDE ® trial evaluating suprachoroidal delivery of surabgene lomparvovec (ABBV-RGX-314, sura-vec) for the treatment of diabetic retinopathy (DR) at the American Academy of Ophthalmology 2025 Annual Meeting. Sura-vec, developed in collaboration with AbbVie, is an investigational one-time gene therapy and potential first-in-class treatment for wet age-related macular degeneration (wet AMD) and DR. Presentation: Suprachoroidal surabgene lomparvovec (sura-vec, ABBV-RGX-314): First time 2-year results in non-proliferative diabetic retinopathy Presenter: Charles C. Wykoff, M.D., PhD, Retina Consultants of Texas Session: Section IX: Late breaking developments, part I Date/Time: October 17, 4:46 p.m. ET About Surabgene Lomparvovec (sura-vec, ABBV-RGX-314) Sura-vec is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy and other chronic retinal conditions. Sura-vec consists of the NAV ® AAV8 vector, which encodes an antibo
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Regenxbio files $300M mixed shelf offering [Seeking Alpha]Seeking Alpha
- REGENXBIO to Participate in Upcoming Investor Conference [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Upcoming Investor ConferencePR Newswire
- REGENXBIO (NASDAQ:RGNX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RGNX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
RGNX
Earnings
- 11/6/25 - Beat
RGNX
Sec Filings
- 11/26/25 - Form S-3
- 11/6/25 - Form 8-K
- 11/6/25 - Form 10-Q
- RGNX's page on the SEC website